Kathryn Shoemaker, MS

Senior Principal Statistician
Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA
Gaithersburg, Maryland, United States

Disclosure information not submitted.

Presentation(s):

• 230 - A Novel SARS-CoV-2 mRNA Virus-Like Particle Vaccine is Highly Potent and Well Tolerated in Adults in a Phase I Randomized Clinical Trial

  Monday, October 20, 2025
  3:15 PM - 3:27 PM US ET